Abstract
BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease of widely varying presentation, which determines functional and psychological impairment, with a high negative impact on patients’ quality of life.Therefore, knowing the patient’s perception of their health status is of fundamental importance for understanding the real impact of PsA. Given this context, the European League Against Rheumatism (EULAR) recently developed the Psoriatic Arthritis Impact of Disease (PsAID) - instrument to specifically assess the impact of PsA for the patient.ObjectiveValidate the brazilian portuguese version of PsAID-12 (Psoriatic Arthritis Impact of Disease) and to verify its interpretability in clinical practice, through its relation with measures of psoriatic arthritis activity.MethodsA multicenter cross-sectional study, which recruited 160 patients, who met the Classification criteria for Psoriatic Arthritis (CASPAR), in six Brazilian centers of rheumatology. Reliability was assessed by Cronbach’s alpha coefficient and by the intraclass correlation coefficient (ICC). The construct validity was evaluated by exploratory factorial analysis and also by Spearman correlation with other PROMs and measures of disease activity evaluation.ResultsOf the total number of participants, 50% were female, with a mean age (SD) of 54.0 ± 11.2 years; 68% had only peripheral arthritis and 32% had pure or mixed axial involvement. The majority (67.7%) of the patients were using biological treatment. The reliability of internal consistency (alpha-Cronbach = 0.93) and test-retest (ICC = 0.996) were good. Factor analysis revealed two factors, named physical and psychosocial, which included the skin evaluation item. PsAID-12 correlated significantly with other PROMs, demonstrating good construct validity. PsAID-12 was also significantly associated with the disease activity assessment instruments (DAS28-ESR, ASDAS, and BASDAI) and the MDA status: “Minimum Disease Activity”. Fibromyalgia did not significantly affect the final PsAID-12 score.ConclusionThe brazilian version of PsAID-12 has been shown to be a reliable and valid measure of the impact of the disease in patients with psoriatic arthritis. Moreover, it associated significantly with the scores of disease activity assessment.
Highlights
Psoriatic arthritis (PsA) is an inflammatory, chronic disease with a complex and heterogeneous presentation
PsAID12 was significantly associated with the disease activity assessment instruments (DAS28-Erythrocyte Sedimentation Rate (ESR), Ankylosing Spondylitis Disease Activity Score (ASDAS), and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)) and the Minimal Disease Activity (MDA) status: “Minimum Disease Activity”
The prevalence of PsA varies among populations, but a study conducted in a large cohort in Brazil found that it affects 33% of individuals with psoriasis (PSO) [1]
Summary
Psoriatic arthritis (PsA) is an inflammatory, chronic disease with a complex and heterogeneous presentation. The prevalence of PsA varies among populations, but a study conducted in a large cohort in Brazil found that it affects 33% of individuals with psoriasis (PSO) [1] This diversity of the clinical spectrum of PsA, activity and potential damage of the disease determine functional and psychological impairment, with a high negative impact on patients’ quality of life. It has been recognized that, in chronic diseases and especially in multifaceted rheumatological conditions such as PsA, the patient’s perception of his health status is of fundamental importance in terms of understanding the real impact of the disease and the shared definition of the treatment target [8, 9] This became even more relevant when studies in patients with psoriatic arthritis had shown divergences between the doctor’s and patient’s views on disease activity [10]. The European League Against Rheumatism (EULAR) recently developed the Psoriatic Arthritis Impact of Disease (PsAID) - instrument to assess the impact of PsA for the patient
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
